McKinley Carter Wealth Services Inc. Increases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

McKinley Carter Wealth Services Inc. increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 64,424 shares of the company’s stock after buying an additional 1,797 shares during the quarter. McKinley Carter Wealth Services Inc.’s holdings in Novo Nordisk A/S were worth $5,542,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. SteelPeak Wealth LLC lifted its holdings in shares of Novo Nordisk A/S by 70.3% during the 4th quarter. SteelPeak Wealth LLC now owns 7,801 shares of the company’s stock worth $671,000 after acquiring an additional 3,220 shares during the period. Mayflower Financial Advisors LLC increased its position in Novo Nordisk A/S by 13.3% during the fourth quarter. Mayflower Financial Advisors LLC now owns 7,613 shares of the company’s stock worth $655,000 after purchasing an additional 894 shares during the last quarter. BSW Wealth Partners raised its stake in Novo Nordisk A/S by 2.3% during the fourth quarter. BSW Wealth Partners now owns 9,296 shares of the company’s stock worth $800,000 after purchasing an additional 213 shares during the period. Stonegate Investment Group LLC boosted its holdings in shares of Novo Nordisk A/S by 4.3% in the 4th quarter. Stonegate Investment Group LLC now owns 31,599 shares of the company’s stock valued at $2,718,000 after purchasing an additional 1,308 shares during the last quarter. Finally, Prospect Financial Services LLC grew its stake in shares of Novo Nordisk A/S by 56.7% during the 4th quarter. Prospect Financial Services LLC now owns 2,667 shares of the company’s stock valued at $229,000 after buying an additional 965 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $85.00 on Wednesday. The company has a market cap of $381.45 billion, a P/E ratio of 27.51, a PEG ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The business’s 50-day simple moving average is $94.75 and its 200 day simple moving average is $114.02. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Analysts Set New Price Targets

Several research analysts recently weighed in on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.